Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica, Benjamin M; Bhatt, Deepak L; Braunwald, Eugene; Steg, P Gabriel; Davidson, Jaime; Hirshberg, Boaz; Ohman, K Peter; Frederich, Robert; Wiviott, Stephen D.; Hoffman, Elaine B; Cavender, Matthew A.; Udell, Jacob A; Desai, Nihar R; Mosenzon, Ofri; McGuire, Darren K; Ray, Kausik K; Leiter, Lawrence A; Raz, Itamar

doi:10.1056/NEJMoa1307684

Record: found
Abstract: found
Article: not found

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Author(s): Benjamin Scirica, Deepak Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, K Ohman, Robert Frederich, Stephen Wiviott, Elaine B Hoffman, Matthew Cavender, Jacob A Udell, Nihar R Desai, Ofri Mosenzon, Darren K McGuire, Kausik K Ray, Lawrence Leiter, Itamar Raz

Publication date: 2013-10-03

Journal: The New England journal of medicine

Publisher: New England Journal of Medicine (NEJM/MMS)

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.